[{"id":"7edb476e-4e8d-4bde-a7cf-d599e9f2f226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076760","created_at":"2021-10-13T16:58:21.457Z","updated_at":"2024-07-02T16:35:17.029Z","phase":"Phase 1","brief_title":"MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05076760","lead_sponsor":"Memgen, Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement","tags":["EGFR • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • MEM-288"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 02/23/2022","start_date":" 02/23/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-02-29"}]